JoshSP, both products Tollovir and Tollovid are ba

JoshSP, both products Tollovir and Tollovid are based on proprietary blends of naturally-derived 3CL protease inhibitors discovered by one of the leading biochemists in the research field on coronaviruses, Dr. Dorit Arad of Israel.

One of the key differences in the Tollo products vs. vaccines and other antivirals is they target the spikes the virus uses to penetrate human cells. The effectiveness of this approach changes as the virus mutates into new strains. In the current Omicron Ba.1 and Ba.2 strains, the research shows the existing vaccines are pretty much ineffective at preventing infection. New vaccines are in development by these will always be several generations behind the latest variants and will lose effectiveness over time as the virus continues to mutate.

Targeting the 3CL protease enzyme produced by the virus initially upon entering the human cell effectively prevents the virus from replicating. Also, since the 3CL protease is responsible for suppressing the body's immune response after infection, the dual-mechanism of preventing replication and allowing the body's immune system to function normally results in the body easily eliminating the Covid infection. This mechanism is common to all coronaviruses, not just Covid-19, and is not likely to change as the virus mutates into new strains. This means that Tollovir/Tollovid will remain fully effective for all strains of Covid, whereby competitors will be left with less effective products that may or may not help at all.

Tollovir and Tollovid have outstanding safety records and data from over 5,000 users to back it up. The phase 2 trial, although small, had outstanding results. No one is expecting FDA to grant an EUA from this trial. They will want to see phase 3 testing results, which the company is currently planning and should start in 2nd quarter. However, numerous countries outside the USA have shown interest in granting EUAs for Tollovir use with the current test results. Greece, Israel, and several others are likely to grant emergency use within the coming weeks or months. Any announcement of those should send the share price much higher.

Todos is also working to get FDA approval for Tollovid as an over-the-counter treatment of non-hospitalized Covid-19 patients. They are currently collecting data from people who have taken the supplement and will present the data to the FDA. Just today they received a sports medicine certification to clear the way for professional athletes to use the product without fear of tripping up on any drug testing issues.

I hold a large long-term position in Todos, as do others who post here. The potential return on this investment is enormous, but will take time since they are a small company competing against the likes of Pfizer, Moderna and Merck. The company has positioned the 3CL technology into a subsidiary called 3CL Pharma so it can be valued separately from the overall company, which has other non-Covid assets in development, and clear the way for a partnership or buyout from any of the big pharma companies. I expect this to happen at some point in the next few weeks or months. The Tollo products are too good to pass up, in my opinion. They are far superior to any other product on the market at present. I am still buying shares. Picked up another 100K shares today.